DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Study to Examine Effect of Recombinant Luteinizing Hormone (r-Lh) and Recombinant Human Chorionic Gonadotropin (r-hCG) for Ovarian Stimulation in Assisted Reproduction Techniques (ART)

Information source: Regionshospitalet Viborg, Skive
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Controlled Ovarian Stimulation; Infertility

Intervention: recombinant luteinizing hormone (r-LH) (Drug); recombinant human chorionic gonadotropin (r-hCG) (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Regionshospitalet Viborg, Skive

Summary

The study is a prospective, randomised, controlled, and non-blinded multi-center pilot study to evaluate endocrine efficacy of recombinant luteinizing hormone versus recombinant human chorionic gonadotropin administered during controlled ovarian stimulation for IVF/ICSI in normogonadotrophic women.

Clinical Details

Official title: The Endocrine Efficacy of Either Recombinant Luteinizing Hormone (r-LH) or Low Dose Recombinant Human Chorionic Gonadotropin (r-hCG) Supplementation for Recombinant Follicle Stimulating Hormone (r-FSH) Stimulation in Normogonadotrophic Women Undergoing in Vitro Fertilization (IVF)/Intracytoplasmic Sperm Injection (ICSI) Therapy Following a Long-term Gonadotropin Releasing Hormone (GnRH) Agonist Down Regulation Protocol

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science

Primary outcome: The Oestradiol Concentration on the Day of Ovulation Induction

Eligibility

Minimum age: 18 Years. Maximum age: 35 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Women who plan to undergo IVF or ICSI treatment

- Woman's age > 18 years but ≤ 35 years

- Regular menstrual cycle (25-34 days)

- BMI 18 to 30 inclusive

- Signed patient information and informed consent forms

Exclusion Criteria:

- PCOS

- More than 2 prior IVF/ICSI attempts

- Diabetes mellitus, epilepsy, lever-, kidney-, heart- and metabolism disorders,

according to the Investigator's assessment.

Locations and Contacts

Fertility Clinic Skive regional Hospital, Skive, Denmark
Additional Information

Starting date: October 2009
Last updated: September 25, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017